92 results on '"Warren, R. B."'
Search Results
2. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study
3. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register
4. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study
5. Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions
6. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients
7. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies
8. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
9. Psoriatic arthritis screening tools: study design and methodologic challenges – reply from authors
10. Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis
11. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)
12. An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene
13. Time for a ‘joint’ approach?
14. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C
15. Cutaneous Mycobacterium haemophilum infection in a patient receiving infliximab for psoriasis
16. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives
17. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
18. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland
19. Psoriasis comorbidities: a worldwide problem?
20. Whatʼs new in psoriasis? An analysis of guidelines and systematic reviews published in 2009–2010
21. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
22. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21
23. Re. major life-changing decisions and cumulative life course impairment
24. Psoriatic arthritis – what the dermatologist needs to know
25. Whatʼs new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009
26. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
27. Psoriasis: is the impairment to a patientʼs life cumulative?
28. Whatʼs new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008
29. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
30. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre
31. Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
32. Methotrexate for psoriasis in the era of biological therapy
33. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
34. Porokeratotic Eccrine Ostial and Dermal Duct Nevus
35. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis
36. Bimekizumab versus Adalimumab in Plaque Psoriasis.
37. SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
38. DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM.
39. SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES.
40. BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE-REFERENCE STUDY BE OPTIMAL.
41. SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR.
42. Craney Island Disposal Area
43. Double-purpose Hospitals in France
44. Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus.
45. What's new in psoriasis treatment? An analysis of systematic reviews published in 2015.
46. Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis.
47. Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab.
48. An evaluation of dermatology patients shielding during the COVID‐19 outbreak.
49. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.
50. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.